• Infixion Bioscience is Awarded Third NIH SBIR Phase 1 Grant to Develop Therapeutics for Neurofibromatosis

    14 days ago - By San Diego Biotechnology

    SAN DIEGO, Sept. 20, 2022 /PRNewswire/ - Infixion Bioscience, a pre-clinical drug discovery company focused on developing gene-targeted therapeutics for the rare genetic disorder Neurofibromatosis Type 1 , announced today the awarding of its third...
    Read more ...

     

  • UC San Diego Receives $16 Million NIH FIRST Award

    14 days ago - By San Diego Biotechnology

    The UC San Diego FIRST Program will recruit 12 diverse, early-career research faculty in the biomedical sciences and the implement strategies to improve faculty recruitment, retention, success and inclusion.
    Read more ...